Background-Few prospective studies have examined quantitative cigarette consumption and smoking cessation on sudden cardiac death (SCD) risk with long-term follow-up. Methods and Results-We prospectively examined the association between cigarette smoking and smoking cessation on the risk of SCD among 101 018 women participating in the Nurses' Health Study without known coronary heart disease, stroke, and cancer at baseline 1980. During 30 years of follow-up, we identified 351 SCD events. Compared with never smokers, current smokers had a 2.44-fold (95% CI, 1.80-3.31) increased risk of SCD after controlling for coronary risk factors. In multivariable analyses, quantity of cigarettes smoked daily (P value for trend, <0.0001) and smoking duration (P value for trend, <0.0001) were linearly associated with SCD risk among current smokers. Small-to-moderate amounts of cigarette consumption (1-14 per day) were associated with a significant 1.84-fold (95% CI, 1.16-2.92) increase in SCD risk and every 5 years of continued smoking was associated with an 8% increase in SCD risk (hazard ratio, 1.08; 95% CI, 1.05-1.12; P<0.0001). The SCD risk linearly decreased over time after quitting and was equivalent to that of a never smoker after 20 years of cessation (P value for trend, <0.0001). Conclusions-In this large prospective cohort of women without coronary heart disease at baseline, a strong dose-response relationship between cigarette smoking and SCD risk was observed, and smoking cessation significantly reduced and eventually eliminated excess SCD risk. This suggests efforts to prevent SCD among women should include aggressive strategies for smoking cessation. (Circ Arrhythm Electrophysiol. 2012;5:1091-1097.)
S udden cardiac death (SCD) is a leading cause of cardiovascular mortality. 1 Most SCDs occur in those without known cardiac disease and not in the well-recognized highrisk subset with myocardial infarction, impaired left-ventricular ejection fraction, and heart failure. 2, 3 Therefore, the current paradigm for SCD prevention does not address the population with the highest number of SCD events. Understanding population-based characteristics that are associated with SCD risk is important for SCD prevention in the general population.
Clinical Perspective on p 1097
Cigarette smoking is strongly associated with SCD risk. [4] [5] [6] [7] [8] [9] Although smoking status is a well-established risk factor for SCD and coronary heart disease (CHD), [10] [11] [12] there are limited data on dose-response relationships between quantity of cigarettes smoked, smoking duration, as well as the impact of smoking cessation on SCD risk over a long-term follow-up.
Data from prospective studies on dose-response relationships appear to conflict. 6, 11, 13 In the Framingham cohort, 13 quantity of cigarettes smoked daily was linearly associated with SCD risk only among men without underlying CHD, whereas a gradient in risk was not observed among patients with a previous history of CHD in the Bezafibrate Infarction Prevention Trial. 11 These studies were limited by relatively few numbers of SCD events, particularly among women. In addition, among patients with known CHD, smoking cessation has been associated with lower incidence of SCD; [10] [11] [12] 14 however, sparse data exist about the benefits of smoking cessation among individuals without documented CHD, who comprise the majority of SCD events in the population. 13 To better define the impact of smoking and cessation among women with and without CHD, we prospectively evaluated the association between amount of cigarette smoking (status, quantity of cigarettes smoked daily, and duration of smoking) and smoking cessation on the risk of SCD among 101 018
Methods The Nurses' Health Study Cohort
The Nurses' Health Study was established in 1976, consisting of 121 701 female registered nurses, 30 to 55 years of age who completed a questionnaire with detailed information about medical history, cardiovascular risk factors, menopausal status, and lifestyle factors. 15 Twice a year, follow-up questionnaires are mailed to update exposure information and ascertain newly diagnosed medical conditions.
Study Population
Follow-up for the present analysis began in 1980 to include important covariates (alcohol use, physical activity, and vitamin use), which were not ascertained until this follow-up period. Women who died before 1980 or with a missing date of death (n=748), had incomplete information about smoking questions (n=4118) or baseline characteristics (n=8634), and previous history of angina, myocardial infarction, coronary revascularization, or stroke or cancer at baseline (n=7183) were excluded leaving 101 018 women who were included in the analysis. Women who reported CHD (angina, myocardial infarction, or coronary revascularization) during follow-up were not excluded from the primary analyses. This study was approved by the Partners Human Research Committee (Boston, MA) and subjects, or family members provided written, informed consent.
Assessment of Smoking and Covariates
Participants reported whether they currently smoked or had ever smoked in the past and the age at which they started smoking on the initial questionnaire. Current smokers reported the number of cigarettes smoked per day. Past smokers reported the age at which they stopped smoking and the number of cigarettes smoked per day before quitting. At the start of each 2-year follow-up cycle, women were reclassified according to most recent smoking status (never, past, current), quantity of cigarettes smoked per day, duration of smoking, and time since quitting among former smokers. We used cigarettes smoked per day and duration of smoking separately instead of a summary measure of pack-years which can classify women with varying doses and duration as having the same pack-years. 16 Covariates including age (continuous), history of diabetes mellitus (yes versus no), history of hypertension (yes versus no), history of hypercholesterolemia (yes versus no), body mass index (<25, 25-29.9, >30 kg/m 2 ), menopausal status and postmenopausal hormone use (yes versus no), usual aspirin use (<1, 1-5, >6 times/wk), multivitamin use (yes versus no), vitamin E use (yes versus no) were updated at the start of each 2-year follow-up cycle. Information on alcohol intake (0, 0.1-4.9, 5.0-14.9, 15.0-29.9, >30 g/d) and physical activity (0, 0-1.9, 2-3.9, >4 h/wk) was updated every 2 to 4 years and family history of myocardial infarction (no, before age 60 years, after age 60 years) was obtained in 1976 and updated in 1984.
End-Point Ascertainment and Definitions
The study end points included incident cases of SCD after the return of the 1980 questionnaire and before January 1, 2011. Deaths were reported by either next of kin, postal authorities or identified through a search of the National Death Index and confirmed with death certificates. We confirmed the end point of SCD through review of medical records, autopsy reports, and interviews with family members about the circumstances surrounding the death. SCD classification has been previously described. 6 Briefly, the pathogenesis of cardiac death was considered sudden if the death or cardiac arrest precipitating death occurred within 1 hour of symptoms. Women with documented collapse of circulation (hypotension, exacerbation of congestive heart failure, or altered mental status) before disappearance of pulse were excluded from arrhythmic deaths to increase specificity. 17 Unwitnessed deaths occurring within 1 hour of symptom onset and with autopsy findings consistent with SCD were considered possible SCDs (n=31) and included in the analysis. In a secondary analysis, we included unwitnessed deaths and deaths that occurred during sleep where the women were documented to be asymptomatic in the preceding 24 hours and where circumstances suggested the death could be sudden (n=117). SCD events were confirmed by 2 cardiologists.
Statistical Analysis
Person-years of follow-up were calculated for each woman from date of return of the 1980 questionnaire to date of death or to January 1, 2011, whichever came first. Women with missing smoking data had nonmissing data carried forward for 1 follow-up cycle. If there was missing data >1 follow-up cycle, person-time was not contributed for respective cycles. All other covariates with missing data had persontime assigned to a missing category for that covariate. In the present analysis, current smokers were classified into categories of cigarettes smoked per day; 1 to 14, 15 to 24, and >25. Current and past smokers were classified as ever smoker to assess duration of smoking which was classified into categories of years: <12, 13 to <24, 25 to <35, and >35. In addition, smoking duration was evaluated as a continuous variable in 5-year increments. For past smokers, cessation was classified into categories of years since quitting of <5, 5 to <10, 10 to <15, 15 to <20, and >20. We used time-varying Cox models to estimate age and multivariable-adjusted hazard ratios (HRs) for SCD across categories of smoking status, cigarettes smoked per day, smoking duration, and years since quitting smoking. Never smoker was the reference group for analyses on smoking status, cigarettes smoked per day, and smoking duration. Current smokers were the reference category for analyses examining smoking cessation among past smokers. Multivariable models adjusted for all covariates.
A Wald test was conducted for linear trend by assigning median values to categories of cigarettes smoked per day, duration of smoking (years), and years since quitting and modeling this variable as a continuous variable. CHD was not controlled for in multivariable models because it is a potential intermediate on the causal pathway between smoking and SCD. To evaluate whether the association between smoking and smoking cessation differs once CHD becomes clinically manifest, a prespecified analysis examining effect modification by history of CHD was performed. To test formally for an interaction between CHD and each smoking variable (status, quantity of daily cigarettes, duration, and years since quitting), we added a cross-product term into separate multivariable models and used a likelihood ratio test, comparing a model with and without the interaction term. We then performed separate multivariable models stratified by CHD status before SCD.
Statistical analyses were performed by using of SAS software version 9.1.3 (SAS Institute Inc, Cary, NC). All probability values were 2-sided and statistically significant at P<0.05.
Results
Among the 101 018 women without known CHD, stroke or cancer at baseline, 29.1% were current smokers, 26.4% past smokers, and 44.5% never smokers. Women who reported current smoking were more likely to be postmenopausal and consumed >15.0 g of alcohol per day. They were less likely to have a body mass index >30 kg/m 2 , regularly use multivitamin or vitamin E, and participate in physical activity >4 h/wk compared with never smokers (Table 1) .
During 30 years of follow-up, there were 351 incident SCDs. Current smoking was associated with a 2.44-fold (95% CI, 1.80-3.31) increased risk of SCD and women who quit smoking had a 1.40-fold (95% CI, 1.10-1.79) increased risk of SCD compared with a never smoker in multivariable analysis ( Table 2) . Compared with women who continued to smoke, women who quit smoking had a lower risk of SCD (HR, 0.58; 95% CI, 0.43-0.77) in multivariable analysis.
In age and multivariable-adjusted models, quantity of cigarettes smoked daily among current smokers was linearly associated with risk of SCD ( Table 2 ; P value for trend <0.0001). Small-to-moderate amounts of daily cigarette consumption (1-14 per day) was significantly associated with a 1.84-fold (95% CI, 1.16-2.92) increase in SCD risk, and women who smoked 25 cigarettes or more had a 3.30fold (95% CI, 2.04-5.33) increase in SCD risk compared with never smokers in multivariable models. Duration of smoking was also linearly associated with SCD risk (Table 3 ; P value for trend <0.0001), with the highest risk associated with a smoking duration >35 years in both age and multivariable-adjusted models (multivariable HR, 2.22; 95% CI, 1.71-2.90). For every 5 years of continued smoking, there was an associated 8% increase in SCD risk (HR, 1.08; 95% CI, 1.05-1.12; P<0.0001) in multivariable analysis.
Compared with current smokers, the HR for SCD linearly decreased among past smokers with length of time since quitting. (Figure; P<0.0001 ). This risk reduction became significant at >15 years of smoking cessation, and by 20 years, the HR for SCD in comparison with women who continued to smoke was similar for past (HR, 0.45; 95% CI, 0.31-0.64) and never smokers (HR, 0.40; 95% CI, 0.30-0.54).
In a secondary analysis, which included unwitnessed deaths where the women were documented to be asymptomatic in the 24 hours preceding death, the association between amount of cigarette smoking and SCD risk was not materially altered. A linear association remained between quantity of cigarettes smoked daily (1-14: HR, 1.74; 95% CI, 1.14-2.66, 15-24: HR, 2.90; 95% CI, 2.04-4.14, >25: HR, 3.12; 95% CI, 1.99-4.90, P value for trend <0.0001) and duration of smoking (<12: HR, 1.35; 95% CI, 0.96-1.88, 13-<24: HR, 1.08; 95% CI, 0.77-1.52, 25-<35: HR, 1.34; 95% CI, 0.97-1.83, >35: HR, 2.42; 95% CI, 1.93-3.03, P value for trend <0.0001) and SCD risk in multivariable analyses. Similarly, SCD risk reduction remained significantly associated with length of time since quitting (P<0.0001).
We explored whether the association between smoking status and SCD differed by the presence or absence of established CHD (Table 4 ). Among women who did not develop CHD, the incidence rate of SCD was 10, 11, and 17 per 100 000 for never, past, and current smokers, respectively. For women who developed CHD, comparable rates were much higher (46, 83, and 78 per 100 000 for never, past, current smokers, respectively). Overall, women with CHD who quit smoking continued to have a higher SCD risk compared with never smokers (HR 1.87, 95% CI, 1.16-3.01); whereas women without CHD did not (P value for interaction=0.15). SCD risk reduction associated with smoking cessation varied significantly among women with and without CHD (P value for interaction=0.03). An immediate reduction in SCD risk at <5 years was observed among women without CHD compared with the risk reduction observed among women with CHD which occurred at 15 to 20 years of smoking cessation. 
Figure.
Age and multivariable-adjusted hazard ratios for SCD according to years since quitting among past smokers. The error bars denote 95% CIs. The reference category is current smokers. The white diamond represents age-adjusted hazard ratio (HR). The black diamond represents multivariable HR adjusted with updated values for age, diabetes mellitus, hypertension, hypercholesterolemia, body mass index, alcohol, physical activity, menopausal status and postmenopausal hormone use, aspirin, multivitamin, vitamin E, and family history of myocardial infarction. P value for trend <0.0001 in the age and multivariable-adjusted models.
The association between quantity of cigarettes smoked daily and duration of smoking and SCD did not significantly vary among women with and without CHD.
Discussion
In this large, long-term, prospective cohort of women without known CHD, stroke or cancer at baseline, quantity and duration of smoking were directly associated with SCD. In multivariable analysis, quantity of cigarettes smoked daily was linearly associated with SCD risk with almost a 2.0fold increase associated with small-to-moderate amounts of cigarette consumption. With respect to smoking cessation, SCD risk reduction linearly increased with length of time since quitting, decreasing to the level of never smoker after 20 years. In stratified analyses, the elevated SCD risk associated with past smoking appeared to be limited to those with established CHD, and the time course of the SCD risk reduction associated with smoking cessation varied significantly among women with and without CHD. An immediate reduction in SCD risk was observed among women without CHD compared with the eventual risk reduction observed among women with CHD.
These data about the association between smoking and SCD in women are generally consistent with those reported in other prospective population-based cohort studies. In a British study of 7735 middle-age men, current smoking was associated with SCD, but only in the absence of ischemic heart disease. 9 In the Framingham Study, smoking >20 cigarettes per day was associated with a long-term elevation in SCD risk among women but not among men. 8 Smoking was not associated with an elevation in short-term risk in women or men. Earlier data from this cohort based on only 50 SCD events suggested a lack of a dose-response relationship between cigarette smoking and SCD among women. 18 Using a total of 351 SCD events, we were able to demonstrate a strong dose-response relationship between quantity of cigarettes smoked daily and SCD risk. Previous studies 5, 18 also suggested that a gradient in SCD risk associated with increasing cigarette use was less apparent once CHD becomes clinically manifest, but we were able to demonstrate direct associations between number of cigarettes smoked among women with and without CHD.
Our data reinforce the important concept that SCD risk associated with cigarette smoking is modifiable. Smoking cessation has previously been associated with SCD risk reduction primarily in populations with established CHD [10] [11] [12] 14 ; whereas a paucity of data exists on smoking cessation and SCD among individuals without CHD. In the Framingham study, male smokers who were <65 at study entry and subsequently quit had half the sudden coronary death rate compared with those who continued to smoke over 18 years of follow-up. 19 Similar to the above studies, we observed a reduction in SCD risk associated with smoking cessation in women. In contrast to previous data suggesting a fairly prompt reduction in SCD risk among patients with CHD, [10] [11] [12] 14 our data suggest that the reduction in SCD risk may be delayed once women develop manifestations of CHD. In this setting, severe and vulnerable coronary atherosclerotic plaques and resultant myocardial fibrosis and scarring may confer a residual SCD risk which persists for some time after smoking cessation. Smoking cessation behavior after a CHD event may also be a function of the nature of CHD events, which in turn could influence residual SCD risk. Women who quit smoking after a CHD event may have had a more severe event than those who continue to smoke resulting in a continued elevation in SCD risk. In contrast, the more immediate SCD risk reduction observed among women without CHD may, in part, be explained by alleviation of acute proarrhythmic effects of nicotine such as reductions in catecholamine release, 20 alteration of potassium handling, 21 and lowering of ventricular fibrillation threshold caused by transient enhanced platelet adhesion. 20 This study has several strengths, including the prospective design, large number of participants with long follow-up, and outcome events confirmed by next-of-kin reports and medical record review. There are also several limitations of the present study which warrant discussion. First, information on cigarette smoking was based on self-report, which could lead to misclassification. However, numerous validation studies have established the accuracy of self-reported smoking and other CHD risk factors in this cohort of health professionals. [22] [23] [24] In addition, smoking characteristics were assessed on 2-year follow-up questionnaires and updated accordingly to further minimize misclassification. Second, determination of SCD is difficult in free-living individuals and is susceptible to error. Accordingly, we tried to minimize error by employing a strict definition of SCD 6 and requiring supporting information from medical records or witnessed reports. These strict criteria would have missed women who died suddenly without supporting information. However, our results were not significantly altered when a sensitivity analysis was performed which included a broader definition of SCD. Third, we did not have direct data about the severity of CHD events to assess the relationship between smoking cessation behavior and CHD events. Fourth, participants of the Nurses' Health Study are predominately white (96%), relatively healthy, and of homogeneous socio-demographic status, and it is uncertain whether these results would be generalizable to other ethnicities and socio-demographic groups. Finally, because of the observational nature of the study, we cannot exclude the possibility that residual or unmeasured confounding may have accounted for part of the associations observed. However, the magnitude of observed associations were not altered substantially after controlling for numerous CHD risk factors, and therefore, residual confounding by these traditional CHD risk factors is unlikely. Conversely, there may be unknown, and thus unmeasured, factors which may mediate or confound the association between smoking and SCD.
In summary, these prospective data provide further evidence that cigarette smoking is an important modifiable risk factor for SCD among women with and without CHD. A dose-dependent relationship between smoking and SCD was observed, and even small-to-moderate quantities of daily smoking were associated with SCD risk. Because SCD is often the first manifestation of CHD among women, 4, 6 lifestyle modifications that reduce SCD in this apparently healthy subset of the population are particularly important. The benefits of smoking cessation on SCD risk in women are in keeping with benefits demonstrated for reductions in all-cause mortality, CHD, and cancer. 25, 26 Smoking cessation was associated with significant reductions in SCD risk in women both with and without CHD. The reduction in SCD risk may be more immediate among women without CHD arguing that efforts at smoking cessation should not await the development of CHD. Efforts to prevent SCD among women should consider aggressive strategies for smoking cessation among all women.
Sources of Funding
This study was supported by research grants CA87969 and HL034594 from the National Institutes of Health and an Established Investigator Award from the American Heart Association to Dr Albert.
